Semaglutide vs tesamorelin compared

Semaglutide and tesamorelin are both FDA-approved peptides. That is where the similarity ends. Semaglutide (Ozempic, Wegovy, Rybelsus) is a GLP-1 receptor agonist with EMA, MHRA and FDA marketing authorisations, backed by randomised trials enrolling tens of thousands of participants^[1]. Tesamorelin (Egrifta) is a GHRH analogue approved by the FDA for one narrow indication, HIV-associated lipodystrophy, and has no marketing authorisation anywhere in the EU, EEA or UK after the European application was withdrawn in 2012^[2]. The gap between them tells you something about how pharmaceutical investment follows market size, and why "FDA-approved" is not a single category.

What semaglutide's approval path looks like

Novo Nordisk brought semaglutide through one of the largest peptide development programmes ever run. The SUSTAIN trials established HbA1c lowering and cardiovascular-event reduction in type-2 diabetes. The STEP programme produced the weight-loss numbers that made GLP-1 agonists front-page news: a mean 14.9% body-weight reduction at 68 weeks in STEP-1^[3]. The SELECT trial then reported a 20% reduction in major adverse cardiovascular events in adults with obesity and pre-existing cardiovascular disease but no diabetes^[4]. That was the first time a weight-loss medication had demonstrated a hard cardiovascular benefit in the obesity-without-diabetes population.

The result of that evidence base is broad regulatory coverage. Ozempic and Rybelsus carry EMA centralised authorisation for type-2 diabetes. Wegovy carries EMA and FDA authorisation for chronic weight management. The MHRA in the UK authorises the same presentations. Reimbursement varies by country and indication, but the regulatory path is global and multi-indication.

What tesamorelin's approval path looks like

Theratechnologies developed tesamorelin for a single clinical target: excess visceral abdominal fat in adults with HIV on antiretroviral therapy who developed lipodystrophy. Two phase-3 trials enrolled 404 and 412 participants respectively. The pooled data showed about a 10.9% reduction in visceral adipose tissue at 26 weeks versus 0.6% on placebo^[5]. The FDA approved Egrifta in November 2010 on the basis of that programme.

Ferrer Internacional submitted the European marketing-authorisation application in May 2011. Thirteen months later, in June 2012, it withdrew the application after the CHMP concluded that the data did not support a positive benefit-risk balance^[2]. No sponsor has re-applied since. The practical consequence is that tesamorelin has no lawful route to patients in the EU, EEA or UK except through named-patient or unlicensed-medicine channels, where a prescribing clinician takes personal responsibility for the import.

Why the paths diverge so sharply

Market size is the short answer. Type-2 diabetes and obesity are among the largest therapeutic markets in the world. HIV-associated lipodystrophy is clinically real but numerically small. Novo Nordisk invested in a multi-indication programme because each new trial opened a new population worth billions in annual revenue. Theratechnologies had a narrower commercial proposition, and when the European regulators pushed back, the economics of a second application apparently did not justify the spend.

This pattern repeats across the peptide landscape. Molecules with large addressable markets attract large trial programmes, which generate large evidence bases, which earn broad regulatory coverage. Molecules with small addressable markets get one or two trials, earn one approval, and stay narrow. The evidence gap between semaglutide and tesamorelin is not mainly a function of the molecules. It is a function of the money behind them.

The grey-market complication

Both peptides circulate outside regulated supply chains. Grey-market vials labelled "semaglutide, for research use only" or "tesamorelin" are sold by online research-chemical vendors. That label does not make either product safe for human use, legal for human consumption, or pharmaceutically equivalent to Ozempic, Wegovy, or Egrifta. Eric Topol has described the broader grey-market peptide market as products "being sold under the rubric of 'research chemicals' to bypass FDA review"^[6].

For semaglutide, the grey-market product competes with a heavily regulated, widely available branded drug. For tesamorelin, the grey-market product may be the only product a reader outside the US can realistically access, because there is no authorised alternative in the EU or UK. That asymmetry matters. A reader who encounters grey-market tesamorelin is more likely to be making a different risk calculation than one who encounters grey-market semaglutide, and the absence of European regulatory coverage shapes that calculation whether the reader knows it or not.

What this comparison does not tell you

These are different drug classes acting on different receptors for different indications. Semaglutide is a GLP-1 receptor agonist targeting appetite, glucose metabolism and cardiovascular risk. Tesamorelin is a GHRH analogue stimulating pulsatile growth-hormone release from the pituitary. Comparing their efficacy head to head would be clinically meaningless because they treat different conditions. The comparison that matters is regulatory and commercial: how much evidence each one has behind it, how broadly each is authorised, and what that means for readers trying to make informed decisions about access.

Where this lands

If you are reading about either peptide, the first question is whether it is authorised in your country for your situation. For semaglutide, the answer is almost certainly yes in the EU, UK and US, on prescription, for one of the labelled indications. For tesamorelin, the answer is yes in the US for HIV-associated lipodystrophy only, and no elsewhere. Country-specific regulatory detail lives on the semaglutide regulation pages and the tesamorelin regulation pages. Any decision about using either peptide belongs with a clinician who knows your history.